Saneron and Henry Ford Health: Cell Therapy Combo Aids Stroke
Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
The battle of the sexes for stroke therapy: female- versus male-derived stem cells.
Human Umbilical Cord Blood Mononuclear Cell Conditioned Media Inhibits Hypoxic-Induced Apoptosis in Human Coronary Artery Endothelial Cells and Cardiac Myocytes by Activation of the Survival Protein Akt.
Combination treatment of stroke with sub-therapeutic doses of Simvastatin and human umbilical cord blood cells enhances vascular remodeling and improves functional outcome.
A single administration of human umbilical cord blood T cells produces long-lasting effects in the aging hippocampus.
Advantages and challenges of alternative sources of adult-derived stem cells for brain repair in stroke.
Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice.
Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.
Human umbilical cord blood mononuclear cells activate the survival protein Akt in cardiac myocytes and endothelial cells that limits apoptosis and necrosis during hypoxia.
Neurological disorders and the potential role for stem cells as a therapy.
Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke.
Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS.
Saneron and South Texas Blood & Tissue Center to Collaborate
Copyright 2013 Saneron CCEL Therapeutics, Inc. All rights reserved. Last updated August 2013